The U.S. Food and Drug Administration (FDA) has classified 20 varieties of ZYN nicotine pouches as Modified Risk Tobacco Products (MRTP). This classification represents the initial instance of an FDA designation for a nicotine pouch product.
This authorization permits PMI U.S. to utilize a specific statement for approved ZYN products, which reads: “Using ZYN instead of cigarettes places you at a lower risk for mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
This approval stems from a thorough scientific evaluation conducted by the FDA. In its official decision, the agency determined that these products, when utilized by consumers as they are typically used, would result in a significant reduction in harm.
The MRTP classification provides a framework for the FDA to assess and categorize tobacco and nicotine products based on their potential health impacts relative to traditional tobacco use. The FDA’s determination emphasizes a comparative risk assessment, allowing the company to communicate a specific public health message regarding the potential benefits of switching from combustible cigarettes to these pouches. This action marks a regulatory milestone for the nicotine pouch category, establishing a precedent for how such products will be regulated and marketed in the future.
The classification underscores the FDA’s ongoing process of evaluating alternative tobacco and nicotine products to manage public health risks.
Topics: #zyn #fda #risk
